HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Rachel Schor-Bardach Selected Research

Antibodies

9/2022Response to Anti-PD1/L1 Antibodies in Advanced Urothelial Cancer in the 'Real-Life' Setting.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Rachel Schor-Bardach Research Topics

Disease

6Neoplasms (Cancer)
09/2022 - 07/2008
3Adenocarcinoma
04/2010 - 07/2008
2Renal Cell Carcinoma (Grawitz Tumor)
04/2011 - 06/2009
1Carcinoma (Carcinomatosis)
09/2022
1Urolithiasis
01/2021
1Necrosis
04/2011
1Body Weight (Weight, Body)
06/2009

Drug/Important Bio-Agent (IBA)

3Sorafenib (BAY 43-9006)FDA Link
04/2011 - 07/2008
1Immune Checkpoint InhibitorsIBA
09/2022
1AntibodiesIBA
09/2022
1Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
04/2011
13-nitrotyrosineIBA
04/2010
1N 30IBA
04/2010
1liposomal doxorubicin (Doxil)FDA Link
04/2010
18-Hydroxy-2'-DeoxyguanosineIBA
04/2010
1Proteins (Proteins, Gene)FDA Link
04/2010
1Caspase 3 (Caspase-3)IBA
04/2010
1Contrast MediaIBA
06/2009
1Angiogenesis InhibitorsIBA
07/2008
1ioversolFDA Link
07/2008

Therapy/Procedure

4Therapeutics
04/2011 - 07/2008
1CT protocol
01/2021
1Replantation
04/2011
1Radiofrequency Ablation
04/2010
1Aftercare (After-Treatment)
04/2010